Biofrontera Inc.
BFRI
$1.54
-$0.02-1.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 32.92% | 17.42% | 36.16% | -22.46% | 15.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.92% | 17.42% | 36.16% | -22.46% | 15.19% |
| Cost of Revenue | -8.78% | -35.25% | -42.92% | -58.07% | -39.15% |
| Gross Profit | 50.17% | 49.77% | 93.37% | 19.54% | 82.67% |
| SG&A Expenses | -8.76% | 26.97% | 6.44% | 23.04% | 33.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.21% | 6.68% | -12.12% | -5.05% | 9.29% |
| Operating Income | 89.68% | 13.61% | 366.30% | -26.57% | -0.16% |
| Income Before Tax | 89.04% | -13.04% | 503.15% | -17.24% | -2,137.55% |
| Income Tax Expenses | 9.52% | -- | 100.00% | 100.00% | 5.00% |
| Earnings from Continuing Operations | 88.66% | -13.06% | 504.01% | -17.29% | -1,971.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 88.66% | -13.06% | 504.01% | -17.29% | -1,971.60% |
| EBIT | 89.68% | 13.61% | 366.30% | -26.57% | -0.16% |
| EBITDA | 90.92% | 14.28% | 375.39% | -29.52% | -2.27% |
| EPS Basic | 91.80% | 14.13% | 362.06% | 37.16% | -1,027.33% |
| Normalized Basic EPS | 92.10% | 14.15% | 329.38% | 37.16% | -1,194.16% |
| EPS Diluted | 91.80% | 14.13% | 362.06% | 37.16% | -1,027.33% |
| Normalized Diluted EPS | 92.10% | 14.15% | 329.38% | 37.16% | -1,194.16% |
| Average Basic Shares Outstanding | 38.20% | 31.66% | 54.17% | 86.64% | 83.67% |
| Average Diluted Shares Outstanding | 38.20% | 31.66% | 54.17% | 86.64% | 83.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |